sigvotatug vedotin + pembrolizumab + carboplatin

This is a combination therapy consisting of **sigvotatug vedotin** (an antibody-drug conjugate reportedly in clinical development), **pembrolizumab** (a monoclonal antibody checkpoint inhibitor targeting PD-1), and **carboplatin** (a platinum-based chemotherapy agent). - Pembrolizumab acts by blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of immune response, leading to increased antitumor activity. - Carboplatin exerts its effect by forming DNA crosslinks, resulting in apoptosis of rapidly dividing cancer cells. - Sigvotatug vedotin is presumed to be an antibody-drug conjugate (ADC), using a monoclonal antibody to target a specific tumor antigen linked to a cytotoxic agent (vedotin is a monomethyl auristatin E derivative), causing targeted cell death. This combination is under clinical investigation for oncology, particularly in settings where chemotherapy and immunotherapy are standard, such as non-small cell lung cancer and other solid tumors.

Other names

sigvotatug vedotinpembrolizumabcarboplatin